SciSparc & Clearmind Pursue Non-Hallucinogenic Depression Therapy with Novel Patent Application

NEW YORK, NY – November 20, 2025

The Rise of Alternative Mental Health Treatments

The mental health landscape is undergoing a significant transformation, moving beyond traditional pharmaceutical interventions toward novel therapies that address unmet needs. SciSparc Ltd. (Nasdaq: SPRC), through its controlling interest in NeuroThera Labs Inc., is at the forefront of this shift, recently filing an Israeli patent application for a novel combination therapy targeting depression. This therapy combines 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), aiming to provide a non-hallucinogenic treatment option for a condition affecting over 332 million people globally. The collaborative effort with Clearmind Medicine Inc. (Nasdaq: CMND) signals a growing industry trend towards alternative approaches to treating mental health disorders.

“The stigma around mental health is diminishing, but access to effective and well-tolerated treatments remains a challenge,” explains one industry analyst. “Companies are actively seeking solutions that address these concerns, and non-hallucinogenic therapies are gaining traction due to their potential for broader patient acceptance and reduced regulatory hurdles.”

A Deep Dive into the MEAI/PEA Combination

The SciSparc/Clearmind therapy centers around a unique combination of MEAI and PEA. MEAI, a selective serotonin releasing agent, has demonstrated potential in mitigating addictive behaviors and improving metabolic health in preclinical studies. It works by selectively increasing serotonin levels in the brain, impacting mood and well-being. PEA, a naturally occurring fatty acid amide, possesses anti-inflammatory and neuroprotective properties. It modulates the endocannabinoid system and regulates inflammatory responses, potentially enhancing the therapeutic effects of MEAI and contributing to overall brain health.

“The synergy between these two compounds is intriguing,” notes a researcher familiar with the therapy’s development. “MEAI targets serotonin pathways directly, while PEA addresses underlying inflammation and supports neuronal function. This multi-faceted approach could offer a more comprehensive treatment for depression than traditional antidepressants, which often focus solely on serotonin reuptake inhibition.”

The companies believe that combining these compounds will provide an effective therapeutic benefit without the undesirable side effects or hallucinogenic properties associated with some psychedelic-based therapies. This focus on non-hallucinogenicity is driven by a desire to broaden patient access and overcome regulatory barriers.

Assessing the Market Potential and Competitive Landscape

The global antidepressant market is substantial, valued at approximately $13.8 billion in 2023 and projected to reach $30.5 billion by 2033, driven by increasing rates of depression and anxiety. However, the current treatment landscape faces significant challenges, including a high rate of treatment-resistant depression, undesirable side effects, and slow onset of action. These challenges create a compelling opportunity for innovative therapies like the SciSparc/Clearmind combination.

Several companies are actively pursuing non-hallucinogenic alternatives to psychedelic-based therapies. Delix Therapeutics and NRx Pharmaceuticals are developing compounds that target similar pathways without inducing hallucinogenic effects. These companies, along with others, are vying for a share of the growing market for alternative mental health treatments. However, SciSparc and Clearmind believe their MEAI/PEA combination offers a unique and compelling value proposition due to its multi-faceted mechanism of action and potential for synergistic effects.

“The key to success in this market will be demonstrating efficacy and safety in clinical trials,” says one investor familiar with the sector. “Companies that can deliver compelling data will be well-positioned to capture a significant share of the market.” SciSparc and Clearmind are preparing to advance their combination therapy through clinical development, with the aim of bringing a novel treatment option to patients suffering from depression. SciSparc’s recent acquisition, transferring its advanced clinical-stage pharmaceutical portfolio, positions the company with resources to scale up research and development efforts.

Financial Considerations and Strategic Implications

Both SciSparc and Clearmind are clinical-stage biotech companies with limited financial resources. SciSparc, with a market capitalization of approximately $3.89 million, is relying on strategic partnerships and efficient capital allocation to advance its drug development programs. Clearmind, with a market capitalization of around $2.20 million, recently secured a $10.0 million securities purchase agreement to support its research and development activities.

The success of the MEAI/PEA combination therapy will depend on securing additional funding and successfully navigating the clinical trial process. However, the potential market opportunity is substantial, and a successful outcome could significantly enhance the value of both companies.

The collaboration between SciSparc and Clearmind demonstrates the growing trend of partnerships in the biotech industry. By combining their expertise and resources, these companies are increasing their chances of success in a highly competitive market. The ongoing patent filings and clinical developments signal a long-term commitment to innovation in the field of mental health.

“This is an exciting time for the mental health industry,” concludes one observer. “The combination of scientific advances, increasing awareness, and a growing demand for effective treatments is creating a fertile ground for innovation. Companies like SciSparc and Clearmind are at the forefront of this transformation, and their efforts could have a profound impact on the lives of millions of people.”